Betty A. Maganda

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients

Betty A. Maganda, Omary Minzi, Eliford Ngaimisi et al. · The Pharmacogenomics Journal · 2015 · 49 citations

Medicine, Pharmacokinetics, Pharmacology +17

Determinants of misuse of antibiotics among parents of children attending clinics in regional referral hospitals in Tanzania

Ritah Mutagonda, Alphonce Ignace Marealle, Lilian Nkinda et al. · Scientific Reports · 2022 · 48 citations · Full text

Public Health, Child Health, Pediatrics +16

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Betty A. Maganda, Eliford Ngaimisi, Appolinary Kamuhabwa et al. · Malaria Journal · 2015 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania

Ritah Mutagonda, Hamu J. Mlyuka, Betty A. Maganda et al. · Journal of the International Association of Providers of AIDS Care (JIAPAC) · 2022 · 30 citations · Full text

Public Health, Child Health, Pediatrics +14

Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy

Betty A. Maganda, Omary Minzi, Appolinary Kamuhabwa et al. · Malaria Journal · 2014 · 27 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17